Catalent offers its partners a wide range of innovative oral dose technologies that can benefit drug developers, and help to improve convenience and patient compliance, while reducing pill burden, which is especially important for vulnerable patient populations.
Catalent has a broad range of experience and expertise in product development, which sees the company support the development and launch of around 200 new products every year.
Leveraging its early-phase development centers of excellence in the U.K. and U.S., and its global network of manufacturing sites, Catalent offers its partners end-to-end solutions for oral dose development.
By adapting for each molecule’s unique characteristics and challenges, Catalent uses its formulation and development experience, and a wide range of technologies to create dose forms that can benefit drug developers, and help to improve convenience and patient compliance, reducing patients’ pill burden. These dose forms include:
R.P. Scherer Softgel Solutions providing optimal drug release profiles through targeted delivery, modified release, coated and fixed dose combinations. Innovations including OptiGel® Bio allow oral delivery of macromolecules, while OptiGel® Micro technology produces smaller, spherical capsules.
OptiShell® Soft Capsules offer formulators the option of higher fill temperatures.
Zydis® Orally Disintegrating Tablets- a unique, freeze-dried oral solid dosage form that disperses almost instantly in the mouth. The new Zydis® Ultra technology provides effective taste masking and increased drug loading for a wider range of active ingredients.
FlexDoseSM technology for the development of easy-to-take doses in stick packs.